Lupin Wins FDA's Tentative Approval For Enzalutamide Tablets Across Multiple Strengths

Lupin received tentative FDA approval for its ANDA for Enzalutamide Tablets in 40 mg, 80 mg, 120 mg, and 160 mg strengths. The regulatory milestone is a positive step toward U.S. generic commercialization, but tentative approval is not final approval and limits near-term impact. The news is favorable for Lupin’s pipeline, though likely only modestly market-moving.

Analysis

Lupin received tentative FDA approval for its ANDA for Enzalutamide Tablets in 40 mg, 80 mg, 120 mg, and 160 mg strengths. The regulatory milestone is a positive step toward U.S. generic commercialization, but tentative approval is not final approval and limits near-term impact. The news is favorable for Lupin’s pipeline, though likely only modestly market-moving.